Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1097/JCP.0000000000001725 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Diagnostic challenges of long COVID in children: a survey of pediatric health care providers' preferences and practices.
Front Pediatr
December 2024
Department of Pediatrics, Harvard Medical School, Boston, MA, United States.
Introduction: Given the challenges in diagnosing children with long COVID, we sought to explore diagnostic practices and preferences among clinicians.
Methods: A ten-question survey assessed pediatric providers' clinical decision making for identifying and evaluating long COVID in children. Of the 120 survey respondents, 84 (70%) were physicians, 31 (26%) nurse practitioners, and 5 (4%) physician assistants.
Effects of face protector devices on acoustic parameters of voice.
Acta Otorhinolaryngol Ital
December 2024
Audiology and Phoniatrics Service, ENT Department, University of Modena e Reggio Emilia, Modena, Italy.
Objectives: The SARS-CoV-2 pandemic required the use of personal protective equipment (PPE) in medical and social contexts to reduce exposure and prevent pathogen transmission. This study aims to analyse possible changes in voice and speech parameters with and without PPE.
Methods: Speech samples using different types of PPE were obtained.
Treatment with Sulodexide Downregulates Biomarkers for Endothelial Dysfunction in Convalescent COVID-19 Patients.
Clin Appl Thromb Hemost
January 2025
Hemostasis and Thrombosis Research Laboratories, Loyola University Medical Center, Maywood, Illinois, USA.
Introduction: Persistent elevation of biomarkers associated with endothelial dysfunction in convalescent COVID-19 patients has been linked to an increased risk of long-term cardiovascular complications, including long COVID syndrome. Sulodexide, known for its vascular endothelial affinity, has demonstrated pleiotropic protective properties. This study aims to evaluate the impact of sulodexide on serum levels of endothelial dysfunction biomarkers in patients during the convalescent phase of COVID-19.
View Article and Find Full Text PDF"Triple and Plan" (TriPla) regimen for long lasting new generation intravitreal anti-VEGF.
Eur J Ophthalmol
January 2025
School of Medicine, Vita-Salute San Raffaele University, Milan, Italy.
Intravitreal injections of anti-vascular endothelial growth factor (anti-VEGF) medications are the primary treatment for neovascular age-related macular degeneration (nAMD). However, frequent administrations pose significant burdens on patients, healthcare providers, and systems. The treat-and-extend (T&E) regimen, which adjusts treatment intervals based on patient response, aims to reduce injection frequency while maintaining disease control.
View Article and Find Full Text PDFImpact of extended-course oral nirmatrelvir/ritonavir in established Long COVID: a case series.
Commun Med (Lond)
January 2025
Patient-Led Research Collaborative, Oakland, CA, USA.
Background: Prior case series suggest that a 5-day course of oral Paxlovid (nirmatrelvir/ritonavir) benefits some people with Long COVID, within and/or outside of the context of an acute reinfection. To the best of our knowledge, there have been no prior case series of people with Long COVID who have attempted longer courses of nirmatrelvir/ritonavir.
Methods: We documented a case series of 13 individuals with Long COVID who initiated extended courses (>5 days; range: 7.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!